There have been few developments in the pharmacotherapy of chronic obstructive pulmonary disease (COPD) that have been so eagerly awaited as that of a long acting anticholinergic compound. For the fi rst time there was a treatment available which was designed with COPD specifi cally in mind. This was not an asthma treatment that had been tried in COPD with more hope than expectation. Tiotropium has now been available in Europe for 5 years and in the US for 3. Has this drug lived up to the expectations with which it was greeted?
in terms of lung function and symptoms, but the study was underpowered to evaluate its primary endpoint of exacerbation rates. Further studies to defi ne properly the benefi ts of such a combined therapy approach are needed. The results of the now complete UPLIFT study are thus eagerly awaited (Decramer et al 2004) .
